American Journal of Managed Care: Semaglutide Enhances Heart Failure Outcomes in Obesity

 1 minute

Sub analyses presented in one of the first late-breaking science presentations at the 2024 European Society of Cardiology Congress show that semaglutide has potential to improve outcomes among patients with obesity-related heart failure with preserved ejection fraction (HFpEF).

Data from the STEP-HFpEF program show benefits in patients with atrial fibrillation (a-fib), as well as improvements in inflammation.

Presented by principal investigator Mikhail Kosiborod, MD, of Saint Luke's Mid America Heart Institute, Kansas City, a sub analysis of data from the STEP-HFpEF and STEP-HFpEF DM trials showed that patients with a-fib have greatly benefited from the GLP-1 receptor agonist, with demonstrated improvements in their heart failure–related symptoms, physical limitations, and exercise abilities, as well as biomarkers of inflammation and heart failure.

Read the full American Journal of Managed Care article: Semaglutide Enhances Heart Failure Outcomes in Obesity